IM Primary vaccination schedule of 2 doses (0.5 mL each): Initial dose followed by 2nd dose 2 mth later. If flexibility in the vaccination schedule is necessary, 2nd dose can be administered between 2 & 6 mth after the 1st dose.
Do not administer intravascularly or intradermally. SC administration is not recommended. Not indicated for prevention of primary varicella infection (chickenpox). Appropriate medical treatment & supervision should always be readily available in case of an anaphylactic event following vaccination. Postpone vaccination in subjects suffering from an acute severe febrile illness. Protective immune response may not be elicited in all vaccinees. No data to support replacing a dose of Shingrix w/ a dose of another herpes zoster vaccine. Individuals w/ thrombocytopenia or any coagulation disorder. Limited data in individuals w/ history of herpes zoster & in frail individuals including those w/ multiple comorbidities. Data on a limited number of immunocompromised subjects w/ HIV or haematopoietic stem cell transplant are available. May have minor influence on the ability to drive & use machines 2-3 days following vaccination. Preferable to avoid use during pregnancy. Lactation.
Can be given concomitantly w/ unadjuvanted inactivated seasonal flu vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23) or reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa); should be administered at different inj sites. More frequent adverse reactions of fever & shivering w/ PPV23 vaccine. Not recommended to concomitantly use w/ other vaccines.